RE: More Motley12 Mar 2021 13:49
Well I did say they were crap at analysing data and I stand by my 20 years of guffawing at their witless offerings.
Aston, what they failed to analyse are 2 particularly attractive sides to the business (telemedecine, and of course the extensive pulonary bio-bank which would be a very sweet acquisition for any pharma in the pulmonary space, and moreover not lost of our institutional investors eyeing thos aspects up too...). As I said, analysis is not Motley's strong point, selling subscriptions is. It's all about the $$$.
But do DYOR. GL.